<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178252</url>
  </required_header>
  <id_info>
    <org_study_id>AYBU1</org_study_id>
    <nct_id>NCT04178252</nct_id>
  </id_info>
  <brief_title>Effectiveness of Eye Mask and Noise Reduction Headset in Primary Headache</brief_title>
  <official_title>Effectiveness of Eye Mask and Noise Reduction Headset in Emergency Treatment of Primary Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara City Hospital Bilkent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara City Hospital Bilkent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary headache can be triggered by light or noise. Getting rest in a quiet and dark
      environment for the treatment of acute headache is recommended for relief of pain during an
      attack. It is hard to provide this kind of environment in a busy emergency department. We
      aimed to determine if eye masks and noise reduction head sets are effective in reducing pain
      scores, fastening pain relief when used together with standard care. We also aimed to see if
      these methods were preferred over standard care.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 8, 2020</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in pain</measure>
    <time_frame>30 min</time_frame>
    <description>Change in pain measured by visual analogue scale from baseline measurement achieved at min 0. Investigators will use a 100mm visual analogue scale in which 0 represents no pain and 100 mm represents worse pain ever</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in pain</measure>
    <time_frame>60 min</time_frame>
    <description>Change in pain measured by visual analogue scale from baseline measurement achieved at min 0. Investigators will use a 100mm visual analogue scale in which 0 represents no pain and 100 mm represents worse pain ever</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>need for rescue analgesic drug</measure>
    <time_frame>60 min</time_frame>
    <description>Patients will be asked in one question if they need any additional analgesic or if they are comfortable enough. If a patients wants additional analgesics, regardless of their pain score measured by Visual analogue scale he/she will be given dexketoprofen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>preference of method over standard treatment</measure>
    <time_frame>60 min</time_frame>
    <description>Patients will be asked in one question if they will prefer the method of treatment that they received in the study in case they have headache in the future</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Primary Headache Disorder</condition>
  <arm_group>
    <arm_group_label>standard drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment of primary headache with 10 mg metoclopramide IV in 150 ml saline given over 10 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug mask</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment plus eye mask</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug headset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment plus headset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>drug mask headset</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment plus headset plus eye mask</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mask</intervention_name>
    <description>investigators will add eye mask to standard treatment</description>
    <arm_group_label>drug mask</arm_group_label>
    <arm_group_label>drug mask headset</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>headset</intervention_name>
    <description>investigators will add headset to standard treatment</description>
    <arm_group_label>drug headset</arm_group_label>
    <arm_group_label>drug mask headset</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard drug</intervention_name>
    <description>investigators will use 10 mg metoclopramide in 150 ml saline given IV over 10 minutes</description>
    <arm_group_label>drug headset</arm_group_label>
    <arm_group_label>drug mask</arm_group_label>
    <arm_group_label>drug mask headset</arm_group_label>
    <arm_group_label>standard drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with current headache as a chief complaint presenting to Emergency Department

          -  triage category 3,4,5.

          -  preliminary clinical diagnosis of primary headache is made after brief history and
             physical exam by the attending emergency physician according to International
             Classification of Headache disorders version 3

          -  the attending physician ordered IV treatment

        Exclusion Criteria:

          -  pregnant

          -  known or suspected diagnosis of a secondary etiology of headache at presentation or at
             any point during the Emergency Department visit

          -  head trauma within 14 days

          -  inability comply with the study due to insufficient knowledge of Turkish language

          -  known allergy to standard treatment or rescue treatment

          -  history of GI bleeding in the last year

          -  taking any analgesic drug in the last four hours or taking the maximum dose of
             standard treatment before coming to Emergency Department

          -  hepatic or renal failure

          -  patients with hearing or vision loss
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gül Pamukçu Günaydın, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara Yildirim Beyazit University Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gül Pamukçu Günaydın, MD</last_name>
    <phone>905325643933</phone>
    <email>gulpamukcu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Çağdaş Yıldırım, MD</last_name>
    <phone>905057106614</phone>
    <email>drcagdasyil@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AnkaraCHBilkent</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gül Pamukçu Günaydın, MD</last_name>
      <phone>905325643933</phone>
      <email>gulpamukcu@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Anagnostou E, Vikelis M, Tzavellas E, Ghika A, Kouzi I, Evdokimidis I, Kararizou E. Photophobia in primary headaches, in essential blepharospasm and in major depression. Int J Neurosci. 2017 Aug;127(8):673-679. doi: 10.1080/00207454.2016.1231185. Epub 2016 Sep 13.</citation>
    <PMID>27580344</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang J, Huang Q, Li N, Tan G, Chen L, Zhou J. Triggers of migraine and tension-type headache in China: a clinic-based survey. Eur J Neurol. 2013 Apr;20(4):689-96. doi: 10.1111/ene.12039. Epub 2013 Jan 28.</citation>
    <PMID>23356519</PMID>
  </results_reference>
  <results_reference>
    <citation>Oktay C, Eken C, Goksu E, Dora B. Contribution of verbal suggestion to the therapeutic efficacy of an analgesic agent for acute primary headache. Cephalalgia. 2015 Jun;35(7):579-84. doi: 10.1177/0333102414553821. Epub 2014 Oct 10.</citation>
    <PMID>25304763</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 8, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara City Hospital Bilkent</investigator_affiliation>
    <investigator_full_name>Gul Pamukcu Gunaydin</investigator_full_name>
    <investigator_title>MD, Faculty Member of Ankara Yildirim Beyazıt University, Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache Disorders</mesh_term>
    <mesh_term>Headache Disorders, Primary</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

